Tirzepatide: the molecule
Tirzepatide is a dual GIP and GLP-1 receptor agonist. That dual mechanism is what distinguishes it from earlier GLP-1-only agonists. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones your gut releases in response to food intake. Tirzepatide mimics both simultaneously.
The GLP-1 component slows gastric emptying, suppresses appetite signaling in the hypothalamus, and modulates insulin and glucagon secretion in a glucose-dependent manner. The GIP component appears to enhance the GLP-1 effect on weight and also independently modulates adipose tissue metabolism and energy expenditure. The combination appears to produce greater weight management effects than GLP-1 agonism alone—a hypothesis borne out in the SURMOUNT trial program.
Tirzepatide was developed by Eli Lilly and approved by the FDA as Mounjaro (for type 2 diabetes management) and subsequently as Zepbound (for weight management in adults with obesity or overweight with a weight-related comorbidity).
What “compounded” means in this context
Pharmaceutical compounding is the preparation of a customized medication by a licensed pharmacy when a commercially available product doesn’t meet a specific patient’s needs. Compounding pharmacies have operated in the United States for decades, primarily preparing custom doses, allergen-free formulations, or alternative delivery forms for patients who can’t use the standard commercial product.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed 503A compounding pharmacies may compound medications for individual patients based on a valid clinician prescription. During an active FDA-designated drug shortage, 503A pharmacies are specifically permitted to compound shortage-listed drugs—which is the legal basis for compounded tirzepatide.
Compound tirzepatide is typically formulated as a subcutaneous injectable solution: tirzepatide API dissolved in a sterile bacteriostatic diluent, prepared under USP sterile compounding standards, dispensed in a vial or pen injector.
How does compound tirzepatide differ from branded Zepbound or Mounjaro?
The active ingredient is the same. Everything else differs:
| Attribute | Zepbound / Mounjaro (branded) | Compound tirzepatide (503A) |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA approval | Yes (Eli Lilly NDA) | No — 503A compounded |
| Manufacturer | Eli Lilly (cGMP facility) | Licensed 503A pharmacy (USP sterile standards) |
| Delivery device | Auto-injector pen | Multi-dose vial with syringe |
| Monthly cost (no insurance) | $1,000–$1,100 | $150–$350 |
| Legal basis | Standard Rx channel | FDA shortage-compounding (subject to change) |
- FDA approval status:Zepbound is FDA-approved. Compound tirzepatide is not. No compounded drug product carries FDA approval—the NDA and post-market studies belong to the branded product, not to compounded preparations.
- Manufacturer: Zepbound is manufactured by Eli Lilly at scale in FDA-inspected facilities. Compound tirzepatide is prepared by a licensed 503A compounding pharmacy in smaller quantities under state pharmacy board oversight.
- Formulation: Zepbound uses the specific pen injector and formulation Lilly developed and tested. Compounded tirzepatide uses a pharmacy-prepared formulation that may differ in diluent, concentration, or delivery device.
- Legal basis for availability:Zepbound is available through standard pharmacy channels with a prescription. Compound tirzepatide is available under shortage-compounding provisions. If the FDA removes tirzepatide from shortage status, the legal basis for compounding it changes.
- Cost:Compounded tirzepatide is substantially less expensive than branded Zepbound at list price, because compounding pharmacies don’t carry R&D amortization or branding costs.
What does the clinical evidence show for tirzepatide?
The clinical evidence for tirzepatide for weight management is extensive and compelling. The SURMOUNT-1 trial, published in the New England Journal of Medicinein 2022, enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, excluding those with type 2 diabetes.
Key SURMOUNT-1 findings:
- 5 mg/week dose: 15.0% mean weight reduction from baseline over 72 weeks.
- 10 mg/week dose: 19.5% mean weight reduction.
- 15 mg/week dose: 20.9% mean weight reduction. In the per-protocol-completer analysis, this reached 22.5%.
- Versus placebo: 3.1% mean weight reduction, confirming that lifestyle advice alone produced modest results in this population.
These figures represent population-level means from a controlled clinical trial. Individual responses vary. Factors including baseline metabolic health, adherence, diet quality, and activity level all influence outcomes. No outcome guarantee applies to any individual patient.
Who is a candidate for compounded tirzepatide?
Clinicians evaluate candidacy based on:
- BMI criteria:The SURMOUNT trials enrolled patients with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Most clinicians use these as the reference standard for prescribing.
- Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) are primary contraindications. Pancreatitis history, severe GI motility disorders, and certain medications are also evaluated.
- Medication interactions: Tirzepatide slows gastric emptying, affecting oral medication absorption timing. A full medication reconciliation is part of the intake process.
- State coverage:Clinician availability varies by state. PepScribe’s clinicians are licensed in a growing number of states—eligibility is confirmed during intake.
The quality difference between 503A pharmacy and gray-market sources
When you obtain compounded tirzepatide through a licensed 503A pharmacy with a valid clinician prescription, you have:
- Pharmaceutical-grade API from FDA-registered suppliers
- Sterility testing and dosing accuracy verification
- State pharmacy board oversight
- A valid prescription from a licensed clinician who reviewed your history
- Ongoing clinical supervision
PepScribe works exclusively with compounding done in the USA by licensed 503A pharmacies. No hidden overseas supply chain. The gray market—research chemical vendors, overseas peptide suppliers, unverified online pharmacies— offers none of these assurances. The cost is lower; the risk is substantially higher.
If a source is offering compounded tirzepatide without a clinician prescription requirement, it is operating outside legal compounding channels.
Frequently asked questions
What is compound tirzepatide?
Compound tirzepatide is a tirzepatide preparation made by a licensed 503A compounding pharmacy, typically as a subcutaneous injectable, formulated and dispensed under a clinician's prescription. It contains the same active ingredient as branded Zepbound and Mounjaro but is not those products and is not FDA-approved.
Is compound tirzepatide legal?
During an active FDA-designated shortage of tirzepatide injection, licensed 503A compounding pharmacies are legally permitted to compound and dispense tirzepatide under a valid clinician prescription. Shortage status is subject to FDA determination and can change.
How does tirzepatide work for weight management?
Tirzepatide activates both GIP and GLP-1 receptors simultaneously. GLP-1 receptor activation slows gastric emptying and suppresses appetite. GIP receptor activation modulates fat storage and energy balance. Together, these mechanisms reduce caloric intake and support body weight management.
What is the difference between compound tirzepatide and Zepbound?
Zepbound is the FDA-approved branded tirzepatide product from Eli Lilly. Compound tirzepatide is a pharmacy-prepared formulation of the same active ingredient. Compound tirzepatide is not FDA-approved, has not undergone the same regulatory review as Zepbound, and is available under shortage-compounding provisions with a clinician's prescription.
What results can I expect from tirzepatide?
The SURMOUNT-1 trial reported mean weight reductions of up to 22.5% over 72 weeks at the 15 mg dose. Individual results vary based on dose, adherence, diet, activity level, and metabolic factors. No outcome guarantees apply — a clinician evaluates your specific situation.